natgillin/translations-raw huggingface dataset:
Allow the vaccine to reach room temperature (15-25 ºC) before administration.
Pred uporabo počakajte, da se cepivo ogreje na sobno temperaturo (15-25 °C).
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
SPC so dovoljene substance za katere tabela 1 priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben, ali pa ne spadajo v področje uporabe Uredbe (ES) št. 470/2009, kadar so uporabljene tako kot v tem zdravilu za uporabo v veterinarski medicini.
Vaccinated animals are able to neutralise the VT2e toxin.
Cepljene živali lahko nevtralizirajo toksin VT2e.
Store and transport refrigerated (2 ºC - 8 ºC).
Shranjujte in prevažajte v hladilniku (2 °C - 8 °C)
EXP {month/year} Once broached use within 10 hours.
EXP {mesec/leto} Odprto zdravilo uporabite v 10 urah.
Sodium hydroxide Disodium phosphate dodecahydrate Potassium chloride Potassium dihydrogen phosphate Sodium chloride
Seznam pomožnih snovi aluminijev hidroksid DEAE-dekstran simetikon natrijev hidroksid natrijev hidrogenfosfat dodekahidrat kalijev klorid kalijev dihidrogenfosfat natrijev klorid voda za injekcije
Administer a single intramuscular injection of 1 ml in the neck muscles.
V vratne mišice dajte eno 1 ml intramuskularno injekcijo.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
- pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Pharmacotherapeutic group: Immunologicals for Suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia).
Farmakoterapevtska skupina: Imunološka zdravila za prašiče, inaktivirana bakterijska cepiva (vključno z mikoplazmo, toksoidom in klamidijo).
Shelf life of the veterinary medicinal product as packaged for sale: 36 months.
Rok uporabnosti zdravila v pakiranju za prodajo: 36 mesecev
The vaccine consisting of recombinant verotoxin 2e stimulates an active immunity against VT2e toxin produced by the causative agent of oedema disease in pigs.
Cepivo z rekombinantnim verotoksinom 2e spodbuja aktivno imunost proti toksinu VT2e, ki ga proizvaja povzročitelj edemske bolezni pri prašičih.
Active immunisation of piglets from 2 days of age to prevent mortality and reduce clinical signs of oedema disease (caused by verotoxin 2e produced by E. coli) and to reduce the loss of daily weight gain during the finishing period in the face of infections with verotoxin 2e producing E. coli until slaughter from 164 days of age.
Aktivna imunizacija pujskov, starejših od 2 dni, za preprečevanje smrtnosti in zmanjšanje kliničnih znakov edemskih bolezni (povzročene z verotoksinom 2e, ki ga proizvaja E. coli) in za zmanjšanje izgube dnevne teže v končnem obdobju pri soočanju z okužbo z verotoksinom 2e, ki ga proizvaja E.
VEPURED suspension for injection for pigs recombinant verotoxin 2e of E. coli
VEPURED suspenzija za injiciranje za prašiče rekombinantni verotoksin 2e iz E. coli
Aluminium hydroxide ............................................................................ 2.117 mg (aluminium) DEAE-dextran
aluminijev hidroksid ................................................................................... 2,117 mg (aluminij) DEAE-dekstran
Major incompatibilities: Do not mix with any other veterinary medicinal product.
Inkompatibilnosti: Ne mešajte z nobenim drugim zdravilomza uporabo v veterinarski medicini.
Very common adverse reactions: - Mild inflammation at the injection site (< 5 cm in diameter) that typically resolves within three days post-vaccination without treatment.
Zelo pogosti neželeni učinki: - blago vnetje na mestu injiciranja (< 5 cm premera), ki običajno izzveni brez zdravljenja v treh dneh po cepljenju.
21 days after vaccination.
Nastop imunosti: 21 dni po cepljenju.
Cardboard box with vials of 10, 50, 100 or 250 doses.
Kartonska škatla z vialami po 10, 50, 100 ali 250 odmerkov.
Marketing authorisation holder and manufacturer responsible for batch release: LABORATORIOS HIPRA, S.A.
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za sproščanje serij: LABORATORIOS HIPRA, S.A.
Shelf life after first opening the container: 10 hours.
Rok uporabnosti po prvem odpiranju vsebnika: 10 ur.
The use is not recommended during pregnancy and lactation.
Uporaba ni priporočljiva v obdobju brejosti in laktacije.
VEPURED suspension for injection for pigs
VEPURED suspenzija za injiciranje za prašiče
10 doses (10 ml) 50 doses (50 ml) 100 doses (100 ml) 250 doses (250 ml) 10 x 10 doses (10 ml)
10 odmerkov (10 ml) 50 odmerkov (50 ml) 100 odmerkov (100 ml) 250 odmerkov (250 ml) 10 x 10 odmerkov (10 ml)
Vial of 100 or 250 doses.
Viala s 100 ali 250 odmerki
Pregnancy and lactation: The use is not recommended during pregnancy and lactation.
Brejost in laktacija: Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena.
Recombinant verotoxin 2e of E. coli ................................................................ RP* ≥ 1.50 * RP - relative potency (ELISA)
rekombinantni verotoksin 2e iz E. coli ............................................................ RP* ≥ 1,50 *RP = relativna potenca (ELISA)
Cardboard box with vial of 10 x10 doses.
Kartonska škatla z vialo z 10 x 10 odmerki.
Vial of 10 or 50 doses
Viala s 10 ali 50 odmerki.
Whitish suspension for injection.
Belkasta suspenzija za injiciranje.
Cardboard box with 1 PET vial of 250 doses (250 ml).
Kartonska škatla z 1 vialo z 250 odmerki (250 ml).
Each dose of 1 ml contains: Recombinant verotoxin 2e of E. coli ................................................................ RP ≥ 1.50.
En 1 ml odmerek vsebuje: rekombinantni verotoksin 2e iz E. coli ............................................................ RP ≥ 1,50 *
Whitish suspension.
Suspenzija belkaste barve.
Cardboard box with 1 vial of 100 doses (100 ml).
Kartonska škatla z 1 vialo s 100 odmerki (100 ml).
Aluminium hydroxide (Al 3+) ........................................................................... 2.117 mg DEAE-dextran ...................................................................................................... 10 mg.
aluminijev hidroksid (Al 3+) ............................................................................. 2,117 mg DEAE-dekstran ............................................................................................ 10 mg
Cardboard box with 1 PET vial of 50 doses (50 ml).
Kartonska škatla z 1 vialo s 50 odmerki (50 ml).
Cardboard box with 10 vials of 10 doses (10 ml).
Kartonska škatla z 10 vialami z 10 odmerki (10 ml).
Polyethylene (PET) vials of 10, 50, 100 and 250 ml.
Polietilenske (PET) viale z vsebino 10, 50, 100 in 250 ml. Viale so zaprte z zamaškom zamaškom iz bromobutilne gume in aluminijasto zaporko.
Cardboard box with 1 vial of 10 doses (10 ml).
Kartonska škatla z 1 vialo z 10 odmerki (10 ml).
Simethicone
OVOJNINAH
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI)
Cardboard box with 1 polyethylene (PET) vial of 10 doses (10 ml).
Velikosti pakiranja: kartonska škatla z 1 polietilen (PET) vialo z 10 odmerki (10 ml) kartonska škatla z 10 PET vialami z 10 odmerki (10 ml).
Invented name Strength Pharmaceutical Form
Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina velikost pakiranja
EU/1/99/124/001 Tractocile 6,75 mg/0,9 ml Solution for injection
Velikost pakiranja raztopina za injiciranje intravenska uporaba koncentrat za raztopino za infundiranje intravenska uporaba
Pharmaceutical Form
Farmacevtska oblika Pot uporabe Stična ovojnina
Concentrate for solution for infusion
Vsebina (koncentracija)
Regulations vary by region.
Predpisi se razlikujejo glede na regijo.
Date of first authorisation: 21st September 2018
Datum prve odobritve: 21. september 2018
Pull straight as shown in pictures 1 and 2.
Potegnite ga naravnost navzdol, kot prikazujeta sliki 1 in 2.
• Place the injector straight onto your skin (about 90 degrees).
• Injektor namestite navpično na kožo (približno 90 stopinj).
• pain in the chest that is not caused by heart disease or a heart attack.
• bolečina v prsih, ki je ne povzročajo srčne bolezni ali srčni infarkt.
• Inject within 5 minutes of removing bottom cap.
• Injicirajte v roku 5 minut od odstranitve spodnjega zamaška.
• Wash hands with soap under warm running water.
• Z milom si umijte roke pod toplo tekočo vodo.
Dispose of bottom cap immediately.
Spodnji zamašek nemudoma zavrzite.
Do this at a speed that is comfortable for you.
Potiskajte s hitrostjo, ki vam najbolj odgovarja.
The instructions how to inject yourself are given below, but proper treatment of your disease requires close and constant co-operation with your doctor.
Spodaj so zapisana navodila za samoinjiciranje zdravila, a ustrezno zdravljenje vaše bolezni zahteva tesno in neprekinjeno sodelovanje z zdravnikom.
Check for any changes in colour, cloudiness or large particles.
Preverite, ali so prisotne spremembe v barvi, motnost ali veliki delci.
Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow, Middlesex HA1 4HF United Kingdom
Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow, Middlesex HA1 4HF Velika Britanija
This does not affect normal operation of the syringe.
To ne vpliva na delovanje brizge.
• if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na pegfilgrastim, filgrastim, ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Your doctor may decide that it would be more convenient for you to inject Pelgraz yourself.
Mogoče se bo zdravnik odločil, da bi bilo za vas prikladneje, če si zdravilo Pelgraz injicirate sami.
Do not warm Pelgraz in any other way (for example, do not warm it in a microwave or in hot water).
Pelgraz ne smete segrevati na kak drug način (na primer, ne segrevajte v mikrovalovni pečici ali v vroči vodi).
No adverse reactions directly attributable to this degree of leukocytosis have been reported.
Ne poročajo o neželenih reakcijah, ki bi jih bilo možno neposredno pripisati tej stopnji levkocitoze.
Acute myeloid leukaemia (AML)
Akutna mieloična levkemija (AML)
If you see blood in the syringe, remove the needle and re-insert it in another place.
Če v injekcijski brizgi opazite kri, izvlecite iglo in jo ponovno vstavite na drugem mestu.
Do not release the pressure on the plunger!
Ne popuščajte pritiska na batu!
If a serious allergic reaction occurs, appropriate therapy should be administered, with close patient follow-up over several days.
primeru resne alergijske reakcije je treba poskrbeti za ustrezno zdravljenje in pazljivo spremljanje bolnika še nekaj dni.
The needle guard will not activate unless the entire dose has been given.
Ščitnik za iglo se ne bo aktiviral, če ni dan celoten odmerek.
The protective sleeve will automatically cover the needle and an audible “click” will be heard to confirm shield activation (see picture 7).
Ščitnik za iglo bo samodejno prekril iglo in slišen bo “klik”, kar potrjuje aktivacijo ščitnika (glejte sliko 7).
Put the needle fully into the skin as shown by your nurse or doctor (see picture 6).
Iglo v celoti zabodite v kožo, kot sta vam pokazala medicinska sestra ali zdravnik (glejte sliko c.
Do not use it if the date has passed the last day of the month shown or if it has been kept outside of the refrigerator for more than 72 hours or has otherwise expired.
Zdravila ne uporabljajte po zadnjem dnevu navedenega meseca ali če je bilo zdravilo shranjeno izven hladilnika dlje kot 72 ur ali je rok uporabnosti potekel drugače.
Common (≥ 1/100 to
Pogosti (≥ 1/100 do
Your doctor has given you Pelgraz to encourage your bone marrow (part of the bone which makes blood cells) to produce more white blood cells that help your body fight infection.
Vaš zdravnik vam je predpisal zdravilo Pelgraz, da bi spodbudilo vaš kostni mozeg (tisti del kosti, ki izdeluje krvničke) k izdelavi več belih krvničk, ki pomagajo vašemu telesu boriti se proti okužbam.
• Injection is completed when the handle has been pushed down as far as possible, you hear a click and the orange body is no longer visible.
• Injiciranje je zaključeno, ko je ročaj popolnoma pritisnjen navzdol, zaslišite klik in oranžni del injektorja več ni viden.
• Inspect liquid in window.
• Skozi okence preglejte tekočino.
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.
• Načrt za obvladovanje tveganja (RMP) Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
(seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in na vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
It is important to tell your doctor if you:
Pomembno je, da poveste zdravniku, če: • ste noseči;
Pelgraz is for use in adults aged 18 and over.
Zdravilo Pelgraz je namenjeno uporabi pri odraslih, starih 18 ali več let.
If someone else is injecting you, they can also use the back of your arms (see picture 4)
Če vam injekcijo daje kdo drug, vam jo lahko da tudi v zadnji del nadlakti (glejte sliko 4).
Before you inject Pelgraz you must do the following:
Pred injiciranjem zdravila Pelgraz morate narediti naslednje:
• inflammation of the aorta (the large blood vessel which transports blood from the heart to the body), see section 2.
• vnetje aorte (velike krvne žile, ki prenaša kri od srca po telesu), glejte poglavje 2.
Disinfect the injection site by using an alcohol swab and pinch the skin between your thumb and forefinger, without squeezing it (see picture 5).
Mesto injiciranja razkužite z alkoholnim zložencem in kožo primite med palec in kazalec, ne da bi jo stiskali (glejte sliko 5).
Pelgraz therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
Zdravljenje z zdravilom Pelgraz morajo uvesti in nadzorovati zdravniki, izkušeni v onkologiji in/ali hematologiji.
The potency of this medicinal product should not be compared to the potency of another pegylated or non-pegylated protein of the same therapeutic class.
Učinkovitosti tega zdravila se ne sme primerjati z učinkovitostjo drugih pegiliranih ali nepegiliranih proteinov iz iste terapevtske skupine.
Your doctor will tell you when to stop using Pelgraz.
Vaš zdravnik vam bo povedal, kdaj morate prenehati jemati zdravilo Pelgraz.
• the abdomen, except for the area around the navel (see picture 3).
• trebuh, razen predela okrog popka (glejte sliko 3).
even if their symptoms of illness are the same as yours.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
Pull slightly on the plunger to check that a blood vessel has not been punctured.
Nekoliko povlecite bat, da se prepričate, da niste prebodli krvne žile.
Such elevation in WBCs is transient, typically seen 24 to 48 hours after administration and is consistent with the pharmacodynamic effects of this medicinal product.
Takšno zvišanje belih krvničk je prehodno, opazimo ga tipično 24 do 48 ur po uporabi zdravila in se sklada s farmakodinamskimi učinki tega zdravila.
The adverse reactions were similar to those in subjects receiving lower doses of pegfilgrastim.
Neželene reakcije so bile podobne tistim pri preiskovancih, ki so prejemali nižje odmerke pegfilgrastima.
If you are injecting yourself and have forgotten your dose of Pelgraz, you should contact your doctor to discuss when you should inject the next dose.
Če si zdravilo injicirate sami in ste pozabili uporabiti odmerek zdravila Pelgraz, se morate posvetovati z zdravnikom, da se bosta dogovorila, kdaj si morate injicirati naslednji odmerek.
If leukocyte counts exceed 50 x 109/L after the expected nadir, this medicinal product should be discontinued immediately.
Če število levkocitov po pričakovanem najmanjšem številu preseže 50 x 109/l, je treba nemudoma prenehati z zdravljenjem s tem zdravilom.
What should I do before I give myself a subcutaneous injection of Pelgraz?
Kaj moram narediti, preden si dam subkutano injekcijo zdravila Pelgraz?
If exposure has been greater than 24 hours or frozen more than once, then Pelgraz should NOT be used.
Če je izpostavljenost daljša od 24 ur ali če je bilo zdravilo zamrznjeno več kot enkrat, zdravila Pelgraz NE SMETE uporabiti.
Your doctor will check your blood and urine regularly as Pelgraz can harm the tiny filters inside your kidneys (glomerulonephritis).
Zdravnik vam bo redno kontroliral kri in urin, kajti zdravilo Pelgraz lahko okvari drobne filtre v ledvicah (povzroči glomerulonefritis).
• Choose injection site (Abdomen or thigh if a patient is injecting himself/herself, with the additional option of the back of the arm if a Healthcare Provider or caregiver is assisting them)
• Izberite mesto injiciranja (trebuh ali stegno, če si bolnik/bolnica zdravilo injicira sam/-a, z dodatno možnostjo injiciranja v zadnji del nadlakti, če mu/ji pri tem pomaga zdravstveni delavec ali negovalec).
Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd PEG molecule.
Pegfilgrastim je kovalenten konjugat rekombinantnega človeškega G-CSF (r-metHuG-CSF) z eno samo molekulo 20kd PEG.
Pelgraz has not been tested in pregnant women.
Zdravila Pelgraz pri nosečnicah niso preskusili.
If you develop or are likely to develop cancers of the blood, you should not use Pelgraz, unless instructed by your doctor.
Če se vam bodo pojavili ali je verjetno, da se vam bodo pojavili krvni raki, ne smete uporabljati zdravila Pelgraz, razen če vam to naroči zdravnik.
Common cases of leukocytosis (WBC > 100 x 109/L) have been reported (see section 4.4).
Pogosto so poročali o primerih levkocitoze (število belih krvničk > 100 x 109/l) (glejte poglavje 4.4).
• abnormal blood test results related to the liver (alanine aminotransferase and aspartate aminotransferase).
• nenormalni rezultati krvnih preiskav, ki so povezani z jetri (alanin-aminotransferaza in aspartat aminotransferaza).
Do not shake Pelgraz vigorously as this may affect its activity.
Zdravila Pelgraz ne smete močno stresati, ker to lahko vpliva na njegovo delovanje.
• Check expiration date on package.
• Preverite datum izteka roka uporabnosti na pakiranju.
What Pelgraz is and what it is used for What you need to know before you use Pelgraz How to use Pelgraz
Kaj je zdravilo Pelgraz in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Pelgraz Kako uporabljati zdravilo Pelgraz
Pelgraz left at room temperature for more than 72 hours should be discarded.
Zdravilo Pelgraz, ki je bilo na sobni temperaturi več kot 72 ur, je treba zavreči.
• Do not lift the injector during injection.
• Injektorja med injiciranjem ne dvigujte.
Each pre-filled syringe or pre-filled injector contains 30 mg sorbitol (E420) (see section 4.4).
Ena napolnjena injekcijska brizga ali en napolnjen injektor vsebuje 30 mg sorbitola (E420) (glejte poglavje 4.4).
• alcohol swab.
• alkoholni zloženec.
This medicinal product contains 50 mg sorbitol in each unit volume, which is equivalent to 30 mg per 6 mg dose.
To zdravilo vsebuje 50 mg sorbitola v vsaki enoti, kar ustreza 30 mg na 6 mg odmerek.
Do not remove the needle cover from the syringe until just before you are ready to inject.
Ne snemite pokrovčka z injekcijske brizge, dokler niste pripravljeni na injiciranje.
Pegfilgrastim has no or negligible influence on the ability to drive and use machines.
Pegfilgrastim nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Check the appearance of Pelgraz.
Preverite videz zdravila Pelgraz.
In order to improve the traceability of biological medicinal products, the trade name of the administered product should be clearly recorded.
Za izboljšanje sledljivosti bioloških zdravil je treba jasno zabeležiti zaščiteno ime uporabljenega zdravila.
Concomitant use of Pelgraz with any chemotherapeutic medicinal product has not been evaluated in patients.
Sočasne uporabe zdravila Pelgraz s katerim koli kemoterapevtskim zdravilom pri bolnikih niso ovrednotili.
Contents of the pack and other information What Pelgraz contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Pelgraz
• abnormal blood test results (lactate dehydrogenase, uric acid and alkaline phosphatase).
• nenormalni rezultati krvnih preiskav (laktat-dehidrogenaza, sečna kislina in alkalna fosfataza).
What Pelgraz is and what it is used for
Kaj je zdravilo Pelgraz in za kaj ga uporabljamo
The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates, and deterioration in pulmonary function along with increased neutrophil count may be preliminary signs of Adult Respiratory Distress Syndrome (ARDS).
Pojav pljučnih znakov, kot so kašelj, zvišana telesna temperatura in dispneja v povezavi z radiološkimi znaki pljučnih infiltratov, in poslabšanje pljučne funkcije skupaj z zvečanim številom nevtrofilcev utegnejo biti preliminarni znaki sindroma dihalne stiske pri odraslem (ARDS - 'Adult Respiratory Distress Syndrome').
Special care should be taken when administering single or combination chemotherapeutic medicinal products which are known to cause severe thrombocytopenia.
Posebna previdnost je potrebna med uporabo posameznih kemoterapevtikov ali njihovih kombinacij, za katere je znano, da povzročajo hudo trombocitopenijo.
Profile of median pegfilgrastim serum concentration and Absolute Neutrophil Count (ANC) in chemotherapy treated patients after a single 6 mg injection
Profil mediane serumske koncentracije pegfilgrastima in absolutnega števila nevtrofilcev (ANC - 'Absolute Neutrophil Count') pri bolnikih, zdravljenih s kemoterapijo, po eni sami 6 miligramski injekciji
Do not dispose of injector in household trash.
Injektorja ne zavrzite med gospodinjske odpadke.
• are aware of any altered blood cell counts (e.g. increase in white blood cells or anaemia) or decreased blood platelet counts, which reduces the ability of your blood to clot (thrombocytopenia).
• ste seznanjeni z morebitnimi spremembami števila krvnih celic (npr. s povečanjem števila belih krvničk ali anemijo) ali z zmanjšanim številom krvnih ploščic v krvi, kar zmanjša sposobnost strjevanja krvi (trombocitopenija).
If you forget to inject Pelgraz
Če ste si pozabili injicirati zdravilo Pelgraz
In the absence of growth factor support, this regimen has been reported to result in a mean duration of grade 4 neutropenia of 5 to7 days, and a 30-40% incidence of febrile neutropenia.
Poročajo, da je ta odmerna shema v odsotnosti podpore s strani rastnega faktorja povzročila nevtropenijo 4. stopnje, ki je povprečno trajala 5 do 7 dni, in 30-40 % incidenco febrilne nevtropenije.
(see section 2).
(glejte poglavje 4.4).
Pegfilgrastim is not recommended during pregnancy and in women of childbearing potential not using contraception.
Pegfilgrastima ne uporabljajte pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.